Business experience
From 20 10 to present, professor and doctoral supervisor of School of Pharmacy, Nankai University;
Since June 2006, 5438, Ali Pharmaceutical Company, senior research scientist;
1September 1998 to May 2006, 5438+0, postdoctoral fellow, Department of Chemistry, University of Colorado, USA;
1July 1990 to1August 1993 Assistant Engineer, Institute of Photosensitive Chemistry, former Ministry of Chemical Industry.
My specialty
Through the study of structure-activity relationship, the lead compounds were optimized and new drugs were developed. Have a certain understanding of the target receptor in the field of receptor protein kinase, and accordingly put forward the project of developing new drugs for cancer treatment; Has the specialty of developing new organic reaction methodology research; Has the specialty of studying the industrial process of organic compounds; Familiar with various analytical instruments (such as NMR, LC-MS, LC, GC, IR and MS). ) to determine the structure and other required characterization of organic compounds.
Published articles
1. Optimize the structure-activity relationship of SERMs for uterine antagonism and ovarian safety. T. Richardson; S. frank; M. Wang; C. Clark; S Jones; B. should; D. Coleman; O Wallace; T. Shepard; R. Daley; A. Palko Witz; A. Gaither; H. Bryant; Heng Ke; I. Cohen; D. Roudman; D. McCann; D. Coutants. oldham; Hummel; Fang Gang; R. Hinkling; G. Lewis; H. Tian; J. dodge Bioorganic and bioengineering. Medicinal Chemistry Letters, 2007, 17( 13), 3544-3549.
2. A selective estrogen receptor modulator designed to treat uterine leiomyoma with unique tissue specificity for rat uterus and ovary. Hummel; A. Gaither; H. Bryant; I. Cohen; R. Daley; Fang Gang; S. frank; R. Hinkling; S Jones; G. Lewis; D. McCann; D. Roudman; T. Shepard; H. Tian; O Wallace; M. Wang; Y. Wang; J. dodge Journal of Medicinal Chemistry, 2005, 48(22), 6772-6775.
3. Asymmetric Strake reaction of G-keto acid. It is easy to enter α-substituted and α, g- disubstituted glutamic acid. Tang, Tian, Ma *, Tetrahedron, 2004,60 (46), 10547- 10552.
4. Asymmetric synthesis of (S)-1-aminoindane-1,5- dicarboxylic acid and related analogues. Ma, Ke, Tian, Wang, Cheng, Tetrahedron: Asymmetric, 2002, 13(9), 96 1-969.
5. Design a new chiral ketone catalyst. Enantioselective epoxidation of cis-and terminal olefins, Tian, She, Shu, Shu, Shi. Chemistry. , 2002, 67(8), 2435-2446.
6. Enantioselective epoxidation of terminal olefins by chiral dioxane. Ritter. , 200 1, 3( 12), 1929- 193 1.
7. Electron probe of asymmetric epoxidized ketone catalyst. Looking for a more powerful catalyst. Ritter. , 200 1, 3(5), 7 15-7 18.
8. enantioselective epoxidation of cis-olefins by chiral dioxane, Tian, She, Shu, Shu, Shi. Chemistry. Socialist, 2000,122,11551-1552.
9. Benzylidene compounds are oxidized to ketone, horse, summer, field and tetrahedron by m-chloroperoxybenzoic acid and oxygen. 1999, 40(50), 89 15-89 17.
10. enantioselective synthesis of a-substituted glutamic acid and a, g- disubstituted glutamic acid by asymmetric Strecker reaction, D. Ma *, G. Tang, H. Tian, G. Zou, Tetrahedron.1999,40 (31).
Asymmetric Strecker type reaction of 1 1.α- aryl ketone. Synthesis of metabotropic glutamate receptor antagonists s-aM4CPG, s-MPPG, s-AIDA and s-APICA. Chemistry. , 1999, 64( 1), 120- 125.
12. stereoselective synthesis of s-MPPG, s-MTPG and s-(+)-aM4CPG from R-4- hydroxyphenylglycine. Socialist Perkin. Transaction 1,1997,23,3493-3496.
13. Synthesis and biological activity of cyclic analogues of sum as metabotropic receptor antagonists. & Medicine. Chemistry. Ritter. , 1997, 7(9), 1 195- 1 198.
14. Asymmetric synthesis of metabotropic glutamate receptor selective antagonist (+)-4CPMG. Tetrahedron: asymmetric,1996,7 (6), 1567- 1570.
Published patent
1. Preparation of pyrrolidone and piperidone derivatives as 1 1-β- hydroxysteroid dehydrogenase 1 inhibitors. Mr. T. Aicher Cicarelli; C. gautier; R. Hinkling; H. Tian; O Wallace.
2. Preparation of pyrrolidone and piperidone as 1 1-β- hydroxysteroid dehydrogenase 1 inhibitors. Mr. T. Aicher Cicarelli; C. gautier; R. Hinkling; H. Tian; O Wallace; Krasucki; J. Allen.
3. Preparation of cycloalkyllactam derivatives as 1 1-β- hydroxysteroid dehydrogenase 1 inhibitors, especially n- substituted pyrrolidine -2- one. Mr. T. Aicher Cicarelli; C. gautier; R. Hinkling; H. Tian; O Wallace; Z. Chen; T. Marbury; J. McCowan; Snyder; L. Wennerowski; J. Allen.
4. Heterobicyclic thiophene compounds as tyrosine kinase inhibitors and their preparation and use. J. Blake; Boyd; J. demis; J. Gaudino; A. Marlowe; J. Seoa. Thomas; Tian. US 2007 197537.
5. Heterobicyclic pyrazole compounds as inhibitors of Met tyrosine kinase, and their preparation and use. J. Blake; Boyd; F. Cohen; J. demis; Fang Gang; J. Gaudino; T. Kaplan; A. Marlowe; J. Seoa. Thomas; H. Tian; W. yang
6. Cyclohexylpyrazole-lactam derivatives as β -hydroxysteroid dehydrogenase 1 inhibitors. T. Aicherp. anzevino; Krasucki; R. Li; T. Marbury; A. Said; Snyder; G. Stephenson; H. Tian; O Wallace; L. Wennerowski; Xu yuanchong. (Note: In addition to the countries specified in WO, the patent has been applied for in another 16 countries).
7. Preparation of quinoline derivatives as tyrosine kinase inhibitors. J. Gaudino; Boyd; A. Marlowe; T. Kaplan; Fang Gang; J.seoh. Tian; J. Blake; K. Koch
8. Heterobicyclic pyrazolopyridine compounds as tyrosine kinase inhibitors and their preparation and use. J. Blake; Boyd; F. Cohen; J. demis; Fang Gang; J. Gaudino; A. Marlowe; J. Seoa. Thomas; H. Tian; W. yang Has been applied.
9. Heterobicyclic azaindole compounds as tyrosine kinase inhibitors and their preparation and use. J. Blake; Boyd; Fang Gang; J. Gaudino; Tian. The manuscript is being prepared.